Abstract
There is mounting evidence both from experimental and clinical studies that traumatic brain injury (TBI) is associated with a reduction of aerobic metabolism. This results from a variable combination of impaired substrate delivery and mitochondrial failure. Mitochondria, which are responsible for the production of 95% of cell adenosine triphosphate (ATP), may become compromised after TBI. On the other hand, in the very early period after the primary injury, oxygen delivery may be impaired due to arterial hypoxia and/or to a reduction of cerebral blood flow (CBF). As a consequence, 80-90% of patients who die of head injury show ischemia on histo-pathological examination of the brain tissue. In the absence of an appropriate treatment for TBI, these observations favored the hypothesis that manipulation of brain oxygen delivery could be a therapeutic tool to improve aerobic metabolism. Several strategies were developed, including the increase of cerebral perfusion pressure (CPP) using amines or the increase of arterial partial pressure of oxygen (PaO2) through hyperbaric oxygen (HBO) or normobaric hyperoxia. Several experimental and clinical studies, using normobaric hyperoxia, demonstrated an increase in brain tissue oxygen tension and a reduction of brain extracellular lactate levels, but there is no consensus about the biological meaning of these findings. For some authors, they translate an improvement of brain oxidative metabolism, while for others they represent only biological epiphenomena. The current review addresses the rational behind normobaric hyperoxia as a therapeutic application and discusses the experimental and clinical results achieved so far.
Keywords: normobaric hyperoxia, traumatic brain injury, aerobic metabolism, brain hypoxia
Current Pharmaceutical Design
Title: Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Volume: 10 Issue: 18
Author(s): O. L. Alves, W. P. Daugherty and M. Rios
Affiliation:
Keywords: normobaric hyperoxia, traumatic brain injury, aerobic metabolism, brain hypoxia
Abstract: There is mounting evidence both from experimental and clinical studies that traumatic brain injury (TBI) is associated with a reduction of aerobic metabolism. This results from a variable combination of impaired substrate delivery and mitochondrial failure. Mitochondria, which are responsible for the production of 95% of cell adenosine triphosphate (ATP), may become compromised after TBI. On the other hand, in the very early period after the primary injury, oxygen delivery may be impaired due to arterial hypoxia and/or to a reduction of cerebral blood flow (CBF). As a consequence, 80-90% of patients who die of head injury show ischemia on histo-pathological examination of the brain tissue. In the absence of an appropriate treatment for TBI, these observations favored the hypothesis that manipulation of brain oxygen delivery could be a therapeutic tool to improve aerobic metabolism. Several strategies were developed, including the increase of cerebral perfusion pressure (CPP) using amines or the increase of arterial partial pressure of oxygen (PaO2) through hyperbaric oxygen (HBO) or normobaric hyperoxia. Several experimental and clinical studies, using normobaric hyperoxia, demonstrated an increase in brain tissue oxygen tension and a reduction of brain extracellular lactate levels, but there is no consensus about the biological meaning of these findings. For some authors, they translate an improvement of brain oxidative metabolism, while for others they represent only biological epiphenomena. The current review addresses the rational behind normobaric hyperoxia as a therapeutic application and discusses the experimental and clinical results achieved so far.
Export Options
About this article
Cite this article as:
Alves L. O., Daugherty P. W. and Rios M., Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384187
DOI https://dx.doi.org/10.2174/1381612043384187 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell-based Therapy for Ocular Disorders: A Promising Frontier
Current Stem Cell Research & Therapy Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Technological Barriers in the Use of Electrochemical Microsensors and Microbiosensors for in vivo Analysis of Neurological Relevant Substances
Current Neuropharmacology Anti-inflammatory and Hypolipidemic Effect of Novel Conjugates with Trolox and Other Antioxidant Acids
Medicinal Chemistry Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer’s Disease
Current Alzheimer Research Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews Potential Therapeutic Properties of Natural Products Through the Expression of Heme Oxygenase-1
Mini-Reviews in Organic Chemistry Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Leukotrienes and Antileukotriene Therapy in Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry